Skip to main content
Top
Published in: Intensive Care Medicine 7/2013

01-07-2013 | Original

Unresponsive thrombotic thrombocytopenic purpura in critically ill adults

Authors: Eric Mariotte, Alice Blet, Lionel Galicier, Michael Darmon, Nathalie Parquet, Etienne Lengline, David Boutboul, Emmanuel Canet, Richard Traineau, Benoît Schlemmer, Agnès Veyradier, Elie Azoulay

Published in: Intensive Care Medicine | Issue 7/2013

Login to get access

Abstract

Introduction

The prognosis of thrombotic thrombocytopenic purpura (TTP) has considerably improved since the introduction of plasma exchange (PEX) therapy. However, unresponsive thrombotic thrombocytopenic purpura (Un-TTP) still carries high morbidity and mortality rates, indicating a need for early specific treatments.

Patients and Methods

In a retrospective study including consecutive adults with TTP admitted between January 1997 and January 2011 in a teaching hospital intensive care unit (ICU), our objective here is to identify early clinical and laboratory features predicting Un-TTP. Patients who responded to plasma exchange and steroids (N = 49) were compared with patients with unresponsive TTP defined as requirement for other treatments, protracted course, or death (N = 37, 43 %).

Results

Hospital mortality was 24.3 % in the Un-TTP group. Variables associated with Un-TTP on univariate logistic regression were older age, cardiac involvement, neurological involvement, higher anti-a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS13) immunoglobulin G (IgG) titer, lower platelet counts starting on day 2, higher Sequential Organ Failure Assessment (SOFA) scores starting on day 3, need for higher plasma volumes to obtain remission, and greater use of adjuvant treatments and life-sustaining interventions. Multivariate logistic regression identified four factors independently associated with Un-TTP: age over 60 years [odds ratio (OR) 7.90; 95 % confidence interval (95 % CI) 1.06–78.34], cardiac (OR 5.17; 95 % CI 1.63–16.39) or neurological (OR 8.04; 95 % CI 1.27–51.03) manifestations at diagnosis, and day 2 platelet count less than 15 G/l (OR 3.88; 95 % CI 1.30–11.62).

Conclusion

Therapeutic intensification starting on day 3 or even earlier in patients with the independent risk factors for unresponsive TTP identified in our study deserves evaluation in a multicenter prospective study.
Literature
4.
go back to reference Moake JL, Rudy CK, Troll JH, Weinstein MJ, Colannino NM, Azocar J, Seder RH, Hong SL, Deykin D (1982) Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med 307:1432–1435. doi:10.1056/NEJM19821202307230629 CrossRefPubMed Moake JL, Rudy CK, Troll JH, Weinstein MJ, Colannino NM, Azocar J, Seder RH, Hong SL, Deykin D (1982) Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med 307:1432–1435. doi:10.​1056/​NEJM198212023072​30629 CrossRefPubMed
5.
go back to reference Tsai HM, Li A, Rock G (2001) Inhibitors of von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura. Clin Lab 47:387–392PubMed Tsai HM, Li A, Rock G (2001) Inhibitors of von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura. Clin Lab 47:387–392PubMed
8.
go back to reference Studt JD, Kremer Hovinga JA, Alberio L, Bianchi V, Lammle B (2003) Von Willebrand factor-cleaving protease (ADAMTS-13) activity in thrombotic microangiopathies: diagnostic experience 2001/2002 of a single research laboratory. Swiss Med Wkly 133:325–332. doi:2003/23/smw-10242smw-10242 PubMed Studt JD, Kremer Hovinga JA, Alberio L, Bianchi V, Lammle B (2003) Von Willebrand factor-cleaving protease (ADAMTS-13) activity in thrombotic microangiopathies: diagnostic experience 2001/2002 of a single research laboratory. Swiss Med Wkly 133:325–332. doi:2003/​23/​smw-10242smw-10242 PubMed
9.
go back to reference Scheiflinger F, Knobl P, Trattner B, Plaimauer B, Mohr G, Dockal M, Dorner F, Rieger M (2003) Nonneutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura. Blood 102:3241–3243. doi:10.1182/blood-2003-05-1616 CrossRefPubMed Scheiflinger F, Knobl P, Trattner B, Plaimauer B, Mohr G, Dockal M, Dorner F, Rieger M (2003) Nonneutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura. Blood 102:3241–3243. doi:10.​1182/​blood-2003-05-1616 CrossRefPubMed
11.
go back to reference Coppo P, Wolf M, Veyradier A, Bussel A, Malot S, Millot GA, Daubin C, Bordessoule D, Pene F, Mira JP, Heshmati F, Maury E, Guidet B, Boulanger E, Galicier L, Parquet N, Vernant JP, Rondeau E, Azoulay E, Schlemmer B (2006) Prognostic value of inhibitory anti-ADAMTS13 antibodies in adult-acquired thrombotic thrombocytopenic purpura. Br J Haematol 132:66–74. doi:10.1111/j.1365-2141.2005.05837.x78 CrossRefPubMed Coppo P, Wolf M, Veyradier A, Bussel A, Malot S, Millot GA, Daubin C, Bordessoule D, Pene F, Mira JP, Heshmati F, Maury E, Guidet B, Boulanger E, Galicier L, Parquet N, Vernant JP, Rondeau E, Azoulay E, Schlemmer B (2006) Prognostic value of inhibitory anti-ADAMTS13 antibodies in adult-acquired thrombotic thrombocytopenic purpura. Br J Haematol 132:66–74. doi:10.​1111/​j.​1365-2141.​2005.​05837.​x78 CrossRefPubMed
12.
go back to reference George JN (2009) The thrombotic thrombocytopenic purpura and hemolytic uremic syndromes: evaluation, management, and long-term outcomes experience of the Oklahoma TTP-HUS Registry, 1989-2007. Kidney Int Suppl: S52–54. doi:10.1038/ki.2008.62277 George JN (2009) The thrombotic thrombocytopenic purpura and hemolytic uremic syndromes: evaluation, management, and long-term outcomes experience of the Oklahoma TTP-HUS Registry, 1989-2007. Kidney Int Suppl: S52–54. doi:10.​1038/​ki.​2008.​62277
16.
go back to reference Viswanathan S, Rovin BH, Shidham GB, Raman SV, Weinberg M, Patricia A, George JN, Wu HM, Cataland SR (2010) Long-term, sub-clinical cardiac and renal complications in patients with multiple relapses of thrombotic thrombocytopenic purpura. Br J Haematol 149:623–625. doi:10.1111/j.1365-2141.2010.08091.x85 CrossRefPubMed Viswanathan S, Rovin BH, Shidham GB, Raman SV, Weinberg M, Patricia A, George JN, Wu HM, Cataland SR (2010) Long-term, sub-clinical cardiac and renal complications in patients with multiple relapses of thrombotic thrombocytopenic purpura. Br J Haematol 149:623–625. doi:10.​1111/​j.​1365-2141.​2010.​08091.​x85 CrossRefPubMed
17.
go back to reference Caramazza D, Quintini G, Abbene I, Coco LL, Malato A, Di Trapani R, Saccullo G, Pizzo G, Palazzolo R, Barone R, Mazzola G, Rizzo S, Ragonese P, Aridon P, Abbadessa V, Siragusa S (2010) Rituximab for managing relapsing or refractory patients with idiopathic thrombotic thrombocytopenic purpura–haemolytic uraemic syndrome. Blood Transfus 8:203–210. doi:10.2450/2009.0101-092 PubMed Caramazza D, Quintini G, Abbene I, Coco LL, Malato A, Di Trapani R, Saccullo G, Pizzo G, Palazzolo R, Barone R, Mazzola G, Rizzo S, Ragonese P, Aridon P, Abbadessa V, Siragusa S (2010) Rituximab for managing relapsing or refractory patients with idiopathic thrombotic thrombocytopenic purpura–haemolytic uraemic syndrome. Blood Transfus 8:203–210. doi:10.​2450/​2009.​0101-092 PubMed
18.
go back to reference Balduini CL, Gugliotta L, Luppi M, Laurenti L, Klersy C, Pieresca C, Quintini G, Iuliano F, Re R, Spedini P, Vianelli N, Zaccaria A, Pogliani EM, Musso R, Bobbio Pallavicini E, Quarta G, Galieni P, Fragasso A, Casella G, Noris P, Ascari E (2010) High versus standard dose methylprednisolone in the acute phase of idiopathic thrombotic thrombocytopenic purpura: a randomized study. Ann Hematol 89:591–596. doi:10.1007/s00277-009-0877-570 CrossRefPubMed Balduini CL, Gugliotta L, Luppi M, Laurenti L, Klersy C, Pieresca C, Quintini G, Iuliano F, Re R, Spedini P, Vianelli N, Zaccaria A, Pogliani EM, Musso R, Bobbio Pallavicini E, Quarta G, Galieni P, Fragasso A, Casella G, Noris P, Ascari E (2010) High versus standard dose methylprednisolone in the acute phase of idiopathic thrombotic thrombocytopenic purpura: a randomized study. Ann Hematol 89:591–596. doi:10.​1007/​s00277-009-0877-570 CrossRefPubMed
22.
go back to reference Allan DS, Kovacs MJ, Clark WF (2001) Frequently relapsing thrombotic thrombocytopenic purpura treated with cytotoxic immunosuppressive therapy. Haematologica 86:844–850PubMed Allan DS, Kovacs MJ, Clark WF (2001) Frequently relapsing thrombotic thrombocytopenic purpura treated with cytotoxic immunosuppressive therapy. Haematologica 86:844–850PubMed
23.
go back to reference Beloncle F, Buffet M, Coindre JP, Munoz-Bongrand N, Malot S, Pene F, Mira JP, Galicier L, Guidet B, Baudel JL, Subra JF, Tanguy-Schmidt A, Pourrat J, Azoulay E, Veyradier A, Coppo P (2012) Splenectomy and/or cyclophosphamide as salvage therapies in thrombotic thrombocytopenic purpura: the French TMA Reference Center experience. Transfusion 52:2436–2444. doi:10.1111/j.1537-2995.2012.03578.x84 CrossRefPubMed Beloncle F, Buffet M, Coindre JP, Munoz-Bongrand N, Malot S, Pene F, Mira JP, Galicier L, Guidet B, Baudel JL, Subra JF, Tanguy-Schmidt A, Pourrat J, Azoulay E, Veyradier A, Coppo P (2012) Splenectomy and/or cyclophosphamide as salvage therapies in thrombotic thrombocytopenic purpura: the French TMA Reference Center experience. Transfusion 52:2436–2444. doi:10.​1111/​j.​1537-2995.​2012.​03578.​x84 CrossRefPubMed
25.
go back to reference Obert B, Tout H, Veyradier A, Fressinaud E, Meyer D, Girma JP (1999) Estimation of the von Willebrand factor-cleaving protease in plasma using monoclonal antibodies to vWF. Thromb Haemost 82:1382–1385PubMed Obert B, Tout H, Veyradier A, Fressinaud E, Meyer D, Girma JP (1999) Estimation of the von Willebrand factor-cleaving protease in plasma using monoclonal antibodies to vWF. Thromb Haemost 82:1382–1385PubMed
26.
go back to reference Peres Bota D, Melot C, Lopes Ferreira F, Nguyen Ba V, Vincent JL (2002) The Multiple Organ Dysfunction Score (MODS) versus the Sequential Organ Failure Assessment (SOFA) score in outcome prediction. Intensive Care Med 28:1619–1624. doi:10.1007/s00134-002-1491-365 CrossRefPubMed Peres Bota D, Melot C, Lopes Ferreira F, Nguyen Ba V, Vincent JL (2002) The Multiple Organ Dysfunction Score (MODS) versus the Sequential Organ Failure Assessment (SOFA) score in outcome prediction. Intensive Care Med 28:1619–1624. doi:10.​1007/​s00134-002-1491-365 CrossRefPubMed
28.
go back to reference Druschky A, Erbguth F, Strauss R, Helm G, Heckmann J, Neundorfer B (1998) Central nervous system involvement in thrombotic thrombocytopenic purpura. Eur Neurol 40:220–224. doi:10.1159/000007983 CrossRefPubMed Druschky A, Erbguth F, Strauss R, Helm G, Heckmann J, Neundorfer B (1998) Central nervous system involvement in thrombotic thrombocytopenic purpura. Eur Neurol 40:220–224. doi:10.​1159/​000007983 CrossRefPubMed
29.
go back to reference Gandhi K, Aronow WS, Desai H, Amin H, Sharma M, Lai HM, Singh P (2010) Cardiovascular manifestations in patients with thrombotic thrombocytopenic purpura: a single-center experience. Clin Cardiol 33:213–216. doi:10.1002/clc.2073111 CrossRefPubMed Gandhi K, Aronow WS, Desai H, Amin H, Sharma M, Lai HM, Singh P (2010) Cardiovascular manifestations in patients with thrombotic thrombocytopenic purpura: a single-center experience. Clin Cardiol 33:213–216. doi:10.​1002/​clc.​2073111 CrossRefPubMed
30.
go back to reference Benhamou Y, Assie C, Boelle PY, Buffet M, Grillberger R, Malot S, Wynckel A, Presne C, Choukroun G, Poullin P, Provot F, Gruson D, Hamidou M, Bordessoule D, Pourrat J, Mira JP, Le Guern V, Pouteil-Noble C, Daubin C, Vanhille P, Rondeau E, Palcoux JB, Mousson C, Vigneau C, Bonmarchand G, Guidet B, Galicier L, Azoulay E, Rottensteiner H, Veyradier A, Coppo P (2012) Development and validation of a predictive model for death in acquired severe ADAMTS13 deficiency-associated idiopathic thrombotic thrombocytopenic purpura: the French TMA Reference Center experience. Haematologica 97:1181–1186. doi:10.3324/haematol.2011.04967687 CrossRefPubMed Benhamou Y, Assie C, Boelle PY, Buffet M, Grillberger R, Malot S, Wynckel A, Presne C, Choukroun G, Poullin P, Provot F, Gruson D, Hamidou M, Bordessoule D, Pourrat J, Mira JP, Le Guern V, Pouteil-Noble C, Daubin C, Vanhille P, Rondeau E, Palcoux JB, Mousson C, Vigneau C, Bonmarchand G, Guidet B, Galicier L, Azoulay E, Rottensteiner H, Veyradier A, Coppo P (2012) Development and validation of a predictive model for death in acquired severe ADAMTS13 deficiency-associated idiopathic thrombotic thrombocytopenic purpura: the French TMA Reference Center experience. Haematologica 97:1181–1186. doi:10.​3324/​haematol.​2011.​04967687 CrossRefPubMed
31.
go back to reference Matsumoto M, Bennett CL, Isonishi A, Qureshi Z, Hori Y, Hayakawa M, Yoshida Y, Yagi H, Fujimura Y (2012) Acquired idiopathic ADAMTS13 activity deficient thrombotic thrombocytopenic purpura in a population from Japan. PLoS One 7:e33029. doi:10.1371/journal.pone.0033029 CrossRefPubMed Matsumoto M, Bennett CL, Isonishi A, Qureshi Z, Hori Y, Hayakawa M, Yoshida Y, Yagi H, Fujimura Y (2012) Acquired idiopathic ADAMTS13 activity deficient thrombotic thrombocytopenic purpura in a population from Japan. PLoS One 7:e33029. doi:10.​1371/​journal.​pone.​0033029 CrossRefPubMed
33.
go back to reference Ferrari S, Scheiflinger F, Rieger M, Mudde G, Wolf M, Coppo P, Girma JP, Azoulay E, Brun-Buisson C, Fakhouri F, Mira JP, Oksenhendler E, Poullin P, Rondeau E, Schleinitz N, Schlemmer B, Teboul JL, Vanhille P, Vernant JP, Meyer D, Veyradier A (2007) Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activity. Blood 109:2815–2822. doi:10.1182/blood-2006-02-0060647 PubMed Ferrari S, Scheiflinger F, Rieger M, Mudde G, Wolf M, Coppo P, Girma JP, Azoulay E, Brun-Buisson C, Fakhouri F, Mira JP, Oksenhendler E, Poullin P, Rondeau E, Schleinitz N, Schlemmer B, Teboul JL, Vanhille P, Vernant JP, Meyer D, Veyradier A (2007) Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activity. Blood 109:2815–2822. doi:10.​1182/​blood-2006-02-0060647 PubMed
35.
go back to reference Darmon M, Azoulay E, Thiery G, Ciroldi M, Galicier L, Parquet N, Veyradier A, Le Gall JR, Oksenhendler E, Schlemmer B (2006) Time course of organ dysfunction in thrombotic microangiopathy patients receiving either plasma perfusion or plasma exchange. Crit Care Med 34:2127–2133. doi:10.1097/01.CCM.0000227659.14644.3E69 CrossRefPubMed Darmon M, Azoulay E, Thiery G, Ciroldi M, Galicier L, Parquet N, Veyradier A, Le Gall JR, Oksenhendler E, Schlemmer B (2006) Time course of organ dysfunction in thrombotic microangiopathy patients receiving either plasma perfusion or plasma exchange. Crit Care Med 34:2127–2133. doi:10.​1097/​01.​CCM.​0000227659.​14644.​3E69 CrossRefPubMed
36.
go back to reference Caramazza D, Quintini G, Abbene I, Malato A, Saccullo G, Lo Coco L, Di Trapani R, Palazzolo R, Barone R, Mazzola G, Rizzo S, Ragonese P, Aridon P, Abbadessa V, Siragusa S (2010) Relapsing or refractory idiopathic thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: the role of rituximab. Transfusion 50:2753–2760. doi:10.1111/j.1537-2995.2010.02763.x CrossRefPubMed Caramazza D, Quintini G, Abbene I, Malato A, Saccullo G, Lo Coco L, Di Trapani R, Palazzolo R, Barone R, Mazzola G, Rizzo S, Ragonese P, Aridon P, Abbadessa V, Siragusa S (2010) Relapsing or refractory idiopathic thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: the role of rituximab. Transfusion 50:2753–2760. doi:10.​1111/​j.​1537-2995.​2010.​02763.​x CrossRefPubMed
37.
go back to reference Froissart A, Buffet M, Veyradier A, Poullin P, Provot F, Malot S, Schwarzinger M, Galicier L, Vanhille P, Vernant JP, Bordessoule D, Guidet B, Azoulay E, Mariotte E, Rondeau E, Mira JP, Wynckel A, Clabault K, Choukroun G, Presne C, Pourrat J, Hamidou M, Coppo P (2012) Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center. Crit Care Med 40:104–111. doi:10.1097/CCM.0b013e31822e9d6680 CrossRefPubMed Froissart A, Buffet M, Veyradier A, Poullin P, Provot F, Malot S, Schwarzinger M, Galicier L, Vanhille P, Vernant JP, Bordessoule D, Guidet B, Azoulay E, Mariotte E, Rondeau E, Mira JP, Wynckel A, Clabault K, Choukroun G, Presne C, Pourrat J, Hamidou M, Coppo P (2012) Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center. Crit Care Med 40:104–111. doi:10.​1097/​CCM.​0b013e31822e9d66​80 CrossRefPubMed
Metadata
Title
Unresponsive thrombotic thrombocytopenic purpura in critically ill adults
Authors
Eric Mariotte
Alice Blet
Lionel Galicier
Michael Darmon
Nathalie Parquet
Etienne Lengline
David Boutboul
Emmanuel Canet
Richard Traineau
Benoît Schlemmer
Agnès Veyradier
Elie Azoulay
Publication date
01-07-2013
Publisher
Springer-Verlag
Published in
Intensive Care Medicine / Issue 7/2013
Print ISSN: 0342-4642
Electronic ISSN: 1432-1238
DOI
https://doi.org/10.1007/s00134-013-2873-4

Other articles of this Issue 7/2013

Intensive Care Medicine 7/2013 Go to the issue

Imaging in Intensive Care Medicine

Excavated pneumonia: an unusual suspect

What's New in Intensive Care

What is new in refractory hypoxemia?